Pancreatic cancer

Clinical trial investigates experimental drug for advanced pancreatic cancer

May 23, 2018

The pancreas, a large gland that sits behind the stomach, produces enzymes that aid digestion and hormones that regulate blood sugar. Pancreatic cancer develops when cells that make up the ducts in the pancreas start to grow out of control. Udo Rudloff, M.D., is leading a clinical trial of a combination immunotherapy regimen to optimally help the immune system attack the tumor. Read more...

Clinical trial investigates experimental drug for advanced pancreatic cancer
T cell

New trial engineers immune cells to treat solid tumors

May 18, 2018

No existing systemic treatments can currently eradicate the great majority of metastatic solid cancers. To meet that need, Steve Rosenberg, M.D., Ph.D., is testing a new immunotherapy that targets each tumor’s unique genetic mutations in a clinical trial. Read more...

New trial engineers immune cells to treat solid tumors
Epstein-Barr virus

New clinical trial uses targeted cancer drug for lymphatic system disease

May 16, 2018

Nivolumab is a targeted cancer drug that blocks the action of a protein called PD-1 and activates T cells to attack cancer cells without damaging normal cells. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is leading a study to determine if nivolumab is effective in treating patients with certain diseases of the lymphatic system. Read more...

New clinical trial uses targeted cancer drug for lymphatic system disease
HPV

Clinical trial tests first-in-class bifunctional immunotherapy drug in HPV-associated cancers

May 14, 2018

HPV-associated cancers that spread or do not respond to treatment are often incurable. Julius Strauss, M.D., of the Laboratory of Tumor Immunology and Biology is testing a first-in-class bifunctional immunotherapy to see if it can control the growth of HPV-associated tumors by restoring and improving the immune system’s ability to kill cancer cells. Read more...

Clinical trial tests first-in-class bifunctional immunotherapy drug in HPV-associated cancers
Dividing Breast Cancer Cell

New trial evaluates investigational drug for endometrial and breast cancers

Apr 24, 2018

A new clinical trial is testing ONC201, an investigational drug that in laboratory studies has been shown to kill breast and endometrial cancer cells most likely by destroying mitochondria within the tumor cells. Mitochondria are the “powerhouse” of the cell, and blocking its activity may kill tumor cells and shrink tumors in human patients. Read more...

New trial evaluates investigational drug for endometrial and breast cancers
Tracie Miller and Steve Lipshultz

A physician faces her own ovarian cancer

Apr 23, 2018

Drs. Tracie Miller and Steve Lipshultz have spent their careers caring for pediatric patients and conducting research at well-known medical institutions across the country. In some ways, those years of providing patient care and conducting medical research prepared the couple for Tracie’s ovarian cancer diagnosis, and in other ways, it didn’t. Read more...

A physician faces her own ovarian cancer
Prostate cancer

Combination immunotherapy clinical trial for prostate cancer patients with rise in PSA

Apr 20, 2018

A new study that is now open is testing combination immunotherapy for men with prostate cancer that are experiencing a rise in PSA after surgery or radiation.  Read more...

Combination immunotherapy clinical trial for prostate cancer patients with rise in PSA
leukemia cells

Phase I clinical trial will test multi-targeted immunotherapy in common childhood cancer

Apr 10, 2018

Chimeric antigen receptor (CAR) T-cell immunotherapy targeting the protein CD19 has shown promise in treating acute lymphoblastic leukemia (ALL). CD22-CAR T-cell therapy has yielded similarly encouraging results, but many patients relapse after either therapy. In an upcoming phase I clinical trial, Center for Cancer Research investigators will test a new strategy—treating patients with a CAR T-cell therapy that targets CD19 and CD22 simultaneously. Read more...

Phase I clinical trial will test multi-targeted immunotherapy in common childhood cancer
Ovarian cancer

New clinical trial studies drug combination for recurring ovarian cancer

Apr 5, 2018

A new clinical trial is studying the effectiveness of an investigational drug combination that looks to see whether reducing the supply of oxygen to the cancer cells can make ovarian cancer shrink or slow its growth in association with an enzyme that repairs DNA damage. Read more...

New clinical trial studies drug combination for recurring ovarian cancer
immunotherapy research

New clinical trial tests prime-and-boost vaccine delivery for advanced solid tumors

Apr 3, 2018

Researchers are testing a prime-and-boost approach to safely direct the immune system to kill tumor cells that express brachyury, a protein expressed in high levels in some cancers. A new clinical trial is testing an experimental vaccine in patients whose cancers have not responded to standard treatments. Read more...

New clinical trial tests prime-and-boost vaccine delivery for advanced solid tumors

Pages